αB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells

Pigment Cell and Melanoma Research

Volumn 23, Issue 2, 2010, Pages 201-209

  Hu, Rong ^a   Aplin, Andrew E ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

B crystallin; B RAF; Cyclin D1; Fbx4; Melanoma

Indexed keywords

ALPHA BETA CRYSTALLIN; B RAF KINASE; BETA CRYSTALLIN; CYCLIN D1; ETOPOSIDE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME; UNCLASSIFIED DRUG; 1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ALPHA CRYSTALLIN; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; BLEOMYCIN; CYCLOHEXIMIDE; LEUPEPTIN; MESSENGER RNA; MUTANT PROTEIN; NITRILE; PROTEIN KINASE INHIBITOR; TETRACYCLINE; ZEOCIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA CELL; MUTANT; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; PROTEIN STABILITY; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MELANOMA; METABOLISM; MUTATION; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ALPHA-CRYSTALLIN B CHAIN; BLEOMYCIN; BUTADIENES; CELLS, CULTURED; CYCLIN D1; CYCLOHEXIMIDE; DNA DAMAGE; ETOPOSIDE; HUMANS; LEUPEPTINS; MELANOCYTES; MELANOMA; MUTANT PROTEINS; MUTATION; NITRILES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TETRACYCLINE;

EID: 77949385731     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2010.00668.x     Document Type: Article

References (28)

1. Alao, J.P. (2007). The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol. Cancer 6, 1-16.
2. Baldwin, E.L., and Osheroff, N. (2005). Etoposide, Topoisomerase II and Cancer. Current Medicinal Chemistry-Anti-Cancer Agents 5, 363-372.
3. Barbash, O., Zamfirova, P., Lin, D.I., Chen, X., Yang, K., Nakagawa, H., Lu, F., Rustgi, A.K., and Diehl, J.A. (2008). Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell 14, 68-78.
4. Bhatt, K.V., Spofford, L.S., Aram, G., Mcmullen, M., Pumiglia, K., and Aplin, A.E. (2005). Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 12, 3459-3471.
5. Bhatt, K.V., Hu, R., Spofford, L.S., and Aplin, A.E. (2007). Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27(Kip1) in human melanoma cells. Oncogene 26, 1056-1066.
6. Cardozo, T., and Pagano, M. (2004). The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell Biol. 5, 739-751.
7. Chelouche-Lev, D., Kluger, H.M., Berger, A.J., Rimm, D.L., and Price, J.E. (2004). alphaB-crystallin as a marker of lymph node involvement in breast carcinoma. Cancer 100, 2543-2548.
8. Conner, S.R., Scott, G., and Aplin, A.E. (2003). Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells. J. Biol. Chem. 278, 34548-34554.
9. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
10. Den Engelsman, J., Keijsers, V., De Jong, W.W., and Boelens, W.C. (2003). The small heat-shock protein alphaB-crystallin promotes FBX4-dependent ubiquitination. J. Biol. Chem. 278, 4699-4704.
11. Diehl, J.A., Zindy, F., and Sherr, C.J. (1997). Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11, 957-972.
12. Guo, Y., Yang, K., Harwalkar, J., Nye, J.M., Mason, D.R., Garrett, M.D., Hitomi, M., and Stacey, D.W. (2005). Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene 24, 2599-2612.
13. Hao, B., Zheng, N., Schulman, B.A., Wu, G., Miller, J.J., Pagano, M., and Pavletich, N.P. (2005). Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol. Cell 20, 9-19.
14. Hu, R., and Aplin, A. (2008). Skp2 regulates G2/M progression in a p53-dependent manner. Mol. Biol. Cell 19, 4602-4610.
15. Kimura, E.T., Nikiforova, M.N., Zhu, Z., Knauf, J.A., Nikiforov, Y.E., and Fagin, J.A. (2003). High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454-1457.
16. Lin, D.I., Barbash, O., Kumar, K.G., Weber, J.D., Harper, J.W., Klein-Szanto, A.J., Rustgi, A., Fuchs, S.Y., and Diehl, J.A. (2006). Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol. Cell 24, 355-366.
17. Liu, J., Suresh Kumar, K.G., Yu, D., Molton, S.A., Mcmahon, M., Herlyn, M., Thomas-Tikhonenko, A., and Fuchs, S.Y. (2007). Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene 26, 1954-1958.
18. Mineva, I., Gartner, W., Hauser, P., Kainz, A., Loffler, M., Wolf, G., Oberbauer, R., Weissel, M., and Wagner, L. (2005). Differential expression of alphaB-crystallin and Hsp27-1 in anaplastic thyroid carcinomas because of tumor-specific alphaB-crystallin gene (CRYAB) silencing. Cell Stress Chaperones 10, 171-184.
19. Moyano, J.V., Evans, J.R., Chen, F. et al. (2006). Alpha B-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J. Clin. Invest. 116, 261-270.
20. Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T.I., Ohtsuru, A., Saenko, V.A., Kanematsu, T., and Yamashita, S. (2003). Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab. 88, 4393-4397.
21. Okabe, H., Lee, S.H., Phuchareon, J., Albertson, D.G., Mccormick, F., and Tetsu, O. (2006). A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS ONE 1, e128.
22. Pagano, M., Theodoras, A.M., Tam, S.W., and Draetta, G.F. (1994). Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev. 8, 1627-1639.
23. Pfaffl, M.W. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucl. Acids Res. 29, e45.
24. Santra, M.K., Wajapeyee, N., and Green, M.R. (2009). F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature 459, 722-725.
25. Satyamoorthy, K., Dejesus, E., Linnenbach, A.J., Kraj, B., Kornreich, D.L., Rendle, S., Elder, D.E., and Herlyn, M. (1997). Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res. 7, S35-S42.
26. Sauter, E.R., Yeo, U.-C., Von Stemm, A. et al. (2002). Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 62, 3200-3206.
27. Spruck, C., Strohmaier, H., Watson, M., Smith, A.P.L., Ryan, A., Krek, W., and Reed, S.I. (2001). A CDK-independent function of mammalian Cks1: targeting of SCFSkp2 to the CDK inhibitor p27Kip1. Mol. Cell 7, 639-650.
28. Wei, S., Yang, H.-C., Chuang, H.-C., Yang, J., Kulp, S.K., Lu, P.-J., Lai, M.-D., and Chen, C.-S. (2008). A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. J. Biol. Chem. 283, 26759-26770.